ArticleNature medicine2025
A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis.
Abstract read
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cerebrospinal fluid inflammatory proteomic profiling identifies biomarkers linked to disease progression in amyotrophic lateral sclerosis.Journal of neurology · 2026Article
- Advancement in therapeutic application of quantum dots in amyotrophic lateral sclerosis: current opportunities and challenges.Drug delivery and translational research · 2026Review
- Artificial Intelligence in Neuromuscular Diseases: Opportunities for a Data-Scarce Field.Neurology and therapy · 2026Review
- Explainable Plasma Proteomics-Based Machine Learning for Osteoporosis Diagnosis, Prognosis, and Protein Biomarker Discovery in the UK Biobank.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Protein Biomarkers in Risk and Prognosis of Amyotrophic Lateral Sclerosis.European journal of neurology · 2026Article
- Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.Nature medicine · 2026Article
- Aptamer-Based Platforms for Human Aging Biomarkers: Multiplexed Proteomics, Biosensors and Translational Perspectives.International journal of molecular sciences · 2026Review
- Proteogenomics in human populations.Nature reviews. Genetics · 2026Review
- Troponin T and Neurofilament Light Chain Levels as Complementary Biomarkers of Disease Accumulation and Aggressiveness in Amyotrophic Lateral Sclerosis.Annals of clinical and translational neurology · 2026Article
- Metabolomic analyses of amyotrophic lateral sclerosis, muscle cramps, and TJ-68 treatment.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Identification of a 10-protein plasma signature for preclinical gout risk beyond serum urate: a robustness-first proteomic study in 33,147 normouricaemic individuals.Journal of translational medicine · 2026Article
- The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.medRxiv : the preprint server for health sciences · 2026Article
- TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026Review
- The hypothalamus is an early site of mitochondrial failure and neuro-immune circuit disruption in amyotrophic lateral sclerosis.Molecular metabolism · 2026Article
- Predicting amyotrophic lateral sclerosis stage based on multi-parameter ultrasound: development and validation of an interpretable machine learning model.BMC medicine · 2026Article
- Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy.Frontiers in immunology · 2026Article
- Strenuous physical activity is associated with a younger age of amyotrophic lateral sclerosis onset in two independent cohorts.Brain communications · 2026Article
- Beyond neurofilaments: a multidimensional blood signature for amyotrophic lateral sclerosis.Brain communications · 2026Article
- Establishing Diagnostic and Differential Diagnostic Criteria for Amyotrophic Lateral Sclerosis.Journal of clinical medicine · 2025Review
- Mapping the circulating proteome across neurodegeneration: A harmonized, consortium-scale framework for uncovering molecular pathophysiology.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Ruth Chia *Neuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4709-7423
Ruin Moaddel *Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6812-0127
Justin Y KwanNeurodegenerative Disorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Memoona RasheedNeuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Paola RuffoNeuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Natalie LandeckNeurodegenerative Diseases Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Paolo RehoNeurodegenerative Diseases Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1423-8680
Rosario VastaNeuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Andrea Calvo'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-5122-7243
Cristina Moglia'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.
Antonio Canosa'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0001-5876-4079
Umberto Manera'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.
Allison SnyderNeurodegenerative Disorders Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1857-928X
Sara Saez-AtienzarDepartment of Neurology, The Ohio State University, Columbus, OH, USA.
Maurizio Grassano'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0001-6714-6897
Maura Brunetti'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.
Federico Casale'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-1097-1279
Anindita RayNeurodegenerative Diseases Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Kumar ArvindNeurodegenerative Diseases Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Betul ComertpayNeuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Min ZhuLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
J Raphael GibbsComputational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6985-0658
American Genome Center
Camille AlbaDepartment of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6459-0893
Liana S RosenthalDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5140-3967
Anna J HallDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexander Y PantelyatDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6427-7485
Derek P NarendraInherited Movement Disorders Unit, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Debra J EhrlichParkinson's Disease Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2663-6766
Keenan A WalkerLaboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5989-9853
Peter KosaLaboratory of Clinical Immunology and Microbiology, Neuroimmunological Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Bibiana BielekovaLaboratory of Clinical Immunology and Microbiology, Neuroimmunological Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0959-9430
Josephine M EganLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8945-0053
Julián CandiaLongitudinal Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5793-8989
Toshiko TanakaLongitudinal Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Luigi FerrucciLongitudinal Studies Section, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6273-1613
Clifton L Dalgard *Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2025-8239
Sonja W Scholz *Neurodegenerative Diseases Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6623-0429
Adriano Chiò *'Rita Levi Montalcini' Department of Neuroscience, Amyotrophic Lateral Sclerosis Center, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0001-9579-5341
Bryan J Traynor *Neuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. bryan.traynor@nih.gov.ORCID http://orcid.org/0000-0003-0527-2446
Funding
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3MGenetic characterization of atypical parkinsonismZIANS003154 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SCHOLZ, SONJA · 2016 to 2025
$15.4MComprehensive multimodal analysis of patients with neuroimmunological diseasesZIAAI001242 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BIELEKOVA, BIBIANA · 2019 to 2025
$12.9MGenome wide SNP analysis in Amyotrophic Lateral SclerosisZIAAG000933 · NIA · NATIONAL INSTITUTE ON AGING · PI TRAYNOR, BRYAN · 2009 to 2025
$9.8MIntramural NIH HHS ZIA AG000933Intramural NIH HHS ZIA AI001242Intramural NIH HHS ZIA NS003154NIA NIH HHS P30 AG066507U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) 1ZIAAG000933
Abstract
Identifying a reliable biomarker for amyotrophic lateral sclerosis (ALS) is crucial for clinical practice. Here, in this cross-sectional study, we used the Olink Explore 3072 platform to investigate plasma proteomics as a biomarker tool for this neurodegenerative condition. Thirty-three proteins were differentially abundant in the plasma of patients with ALS (n = 183) versus controls (n = 309). We replicated our findings in an independent cohort (n = 48 patients with ALS and n = 75 controls). We then applied machine learning to create a model that diagnosed ALS with high accuracy (area under the curve, 98.3%). By analyzing plasma samples from individuals before ALS symptoms emerged, we estimated the age of clinical onset and showed that the disease process-impacting skeletal muscle, nerves and energy metabolism-occurs years before symptoms appear. Our research suggests that plasma proteins can be a biomarker for this fatal disease and offers molecular insights into its prodromal phase.
Indexed as
Amyotrophic Lateral SclerosisBiomarkersBlood ProteinsProteomicsAdultAgedCase-Control StudiesCross-Sectional StudiesFemaleHumansMachine LearningMaleMiddle AgedBiomarkersBlood Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.